Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel Angiotensinogen (AGT)-Targeting siRNA Drug for Hypertension
Rona Therapeutics, a Shanghai-based biotech company focused on RNA-targeted therapies, announced that its Investigational New Drug (IND) application for RN1871 has been approved by China’s National Medical Products Administration (NMPA). RN1871 is a small interfering RNA (siRNA) therapy designed to silence angiotensinogen (AGT) mRNA in the liver, thereby suppressing the Renin-Angiotensin-Aldosterone System (RAAS), a key regulator of blood pressure.
RAAS overactivation is a major contributor to hypertension, which affects more than 1.5 billion people globally. Preclinical data show that RN1871 provides long-lasting blood pressure control with infrequent dosing and a favorable safety profile. Rona now plans to initiate a Phase I clinical trial to evaluate RN1871’s safety, pharmacokinetics, and early efficacy in humans.
CEO Stella Shi emphasized the breakthrough nature of this siRNA-based approach to treating chronic diseases, offering a more compliant and potentially safer therapy for hypertension. Chief Medical Officer Dr. Alex M. DePaoli highlighted RN1871’s potent AGT suppression and its potential to improve cardiovascular outcomes.
Rona Therapeutics specializes in nucleic acid therapeutics for cardiometabolic and neurological diseases, and is advancing both hepatic and extra-hepatic delivery platforms to address unmet medical needs with differentiated siRNA therapies.
Source:
https://www.prnewswire.com/news-releases/rona-therapeutics-announces-nmpa-approval-of-ind-application-for-rn1871-a-novel-angiotensinogen-agt-targeting-sirna-drug-for-hypertension-302432290.html
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
